NHF-McMaster Guideline on Care Models for Haemophilia Management

Haemophilia

Volumn 22, Issue , 2016, Pages 6-16

  Pai, M ^a,b   Key, N S ^c   Skinner, M ^d   Curtis, R ^e   Feinstein, M ^f   Kessler, C ^g   Lane, S J ^b   Makris, M ^h   Riker, E ^f   Santesso, N ^a   Soucie, J M ⁱ   Yeung, C H T ^a   Iorio, A ^a   Schunemann H J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Institute for Policy Studied   (United States)

^e Factor VIII Computing   (United States)

^f National Hemophilia Foundation   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

care model; delivery of health care; guideline; haemophilia; health care team; integrated care

Indexed keywords

ASTHMA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; EVIDENCE BASED PRACTICE; EXERCISE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEART FAILURE; HEMATOLOGIST; HEMOPHILIA; HUMAN; INTEGRATIVE MEDICINE; MEDICAL SOCIETY; NURSE; PHYSIOTHERAPIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SOCIAL PSYCHOLOGY; SOCIAL WORKER; SYSTEMATIC REVIEW; TEAMWORK; UNITED STATES;

EID: 84976627739     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13008     Document Type: Review

References (34)

1. National Hemophilia Foundation. Strategic Summit Report. The Lewin Group; 2012.
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47.
3. Colvin BT, Astermark J, Fischer K et al. European principles of haemophilia care. Haemophilia 2008; 14: 361–74.
4. Hemophilia and von Willebrand's disease. 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada. CMAJ 1995; 153: 19–25.
5. Street A. Developing models of haemophilia care. Haemophilia 2012; 18 (Suppl. 4): 89–93.
6. Evatt BL, Black C, Batorova A, Street A, Srivastava A. Comprehensive care for haemophilia around the world. Haemophilia 2004; 10 (Suppl. 4): 9–13.
7. Ruiz-Sáez A. Comprehensive care in hemophilia. Hematology 2012; 17 (Suppl. 1): S141–3.
8. Aschman DJ, Abshire TC, Shapiro AD, Lusher JM, Forsberg AD, Kulkarni R. A community-based partnership to promote information infrastructure for bleeding disorders. Am J Prev Med 2011; 41 (Suppl. 4): S332–7.
9. De Kleijn P, Odent T, Berntorp E et al. Differences between developed and developing countries in paediatric care in haemophilia. Haemophilia 2012; 18 (Suppl. 4): 94–100.
10. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 474–80.
11. Miners AH. Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? Haemophilia 2013; 19: 174–80.
12. Feldman BM, Aledort L, Bullinger M et al. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia 2007; 13: 745–9.
13. Baker JR, Crudder SO, Riske B, Bias V, Forsberg A. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health 2005; 95: 1910–6.
14. Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437–42.
15. Soucie JM, Symons J, Evatt B et al. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001; 7: 198–206.
16. Clinical Practice Guidelines We Can Trust [Internet]. Washington, D.C.: National Academies Press; 2011 [cited 2015 Dec 23]. Available from: http://www.nap.edu/catalog/13058. Accessed January 16, 2016.
17. Brożek JL, Akl EA, Compalati E et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011; 66: 588–95.
18. Brozek JL, Akl EA, Alonso-Coello P et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009; 64: 669–77.
19. Brozek JL, Akl EA, Jaeschke R et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 2009; 64: 1109–16.
20. Schünemann HJ, Al-Ansary LA, Forland F et al. Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. Ann Intern Med 2015; 163: 548–53.
21. Pai M, Santesso N, Yeung CHT, Lane SJ, Schünemann HJ, Iorio A. Methodology for the development of the NHF-McMaster guideline on care models for haemophilia management. Haemophilia 2016; 22 (Suppl 3): 17–22.
22. Andrews J, Guyatt G, Oxman AD et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719–25.
23. Andrews JC, Schünemann HJ, Oxman AD et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013; 66: 726–35.
24. Zhou Z-Y, Koerper MA, Johnson KA et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ 2015; 18: 457–65.
25. Castaman G, Fijnvandraat K. Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A. Blood 2014; 124: 2333–6.
26. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12 (Suppl. 6): 15–22.
27. Nugent D, Kalnins W, Querol F et al. Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population. Haemophilia 2015; 21: e26–38.
28. Forsyth AL, Witkop M, Lambing A et al. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Prefer Adherence 2015; 9: 1549–60.
29. Michael R, Mulder K, Strike K Exercise for hemophilia (Protocol). 2014; (7. Art. No.: CD011180. doi: 10.1002/14651858.CD011180).
30. Cassis F, Kalnins W, Wisniewski T, Cooper D, Iorio A. Potential Relationships Between Negative Impacts on Employment or Relationships and Haemophilia Treatment Centre and Provider Utilisation: An Analysis of Adults With Haemophilia in the HERO Study. The Netherlands: XXIV Congress of the International Society on Thrombosis and Haemostasis Amsterdam, 2013.
31. Srivastava A. Haemophilia care – beyond the treatment guidelines. Haemophilia 2014; 20 (Suppl. 4): 4–10.
32. Coppola A, Santoro C, Franchini M et al. Emerging issues on comprehensive hemophilia care: preventing, identifying, and monitoring age-related comorbidities. Semin Thromb Hemost 2013; 39: 794–802.
33. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447–56.
34. Giangrande P, Calizzani G, Menichini I, Candura F, Mannucci PM, Makris M. The European standards of Haemophilia Centres. Blood Transfus 2014; 12 (Suppl. 3): s525–30.